Interestingly, since GRP94 specifically interacts with HER2 on the plasma membrane of some tumor cells, blocking this interaction with specific antibodies could be of benefit in HER2-positive breast cancer [117,118]. This evidence concerns the gene ERBB2 and breast carcinoma.